Overview

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Status:
Recruiting
Trial end date:
2029-10-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
AMG 757